Cardiff Medtech Firm Alesi Surgical Lands Major £7 Million Investment
Cardiff-based surgical technology company Alesi Surgical has successfully closed a substantial £7 million funding round, which will fuel its ambitious growth plans and international expansion. The investment was spearheaded by IW Capital, with strong backing from existing shareholders IP Group and Mercia Ventures.
Tackling a Critical Operating Theatre Hazard
Surgical smoke, a byproduct generated in approximately 90% of surgical procedures—totalling an estimated 266 million operations annually—poses significant risks in operating theatres worldwide. This smoke not only obscures surgeons' visibility during delicate procedures but also exposes healthcare professionals and patients to harmful aerosols and particulate matter.
Historically, the adoption of smoke management solutions has been hindered by cumbersome extraction systems that disrupt surgical workflow. However, growing regulatory momentum, particularly in the United States where 20 states have now enacted legislation, is accelerating a shift toward smoke-free operating theatres becoming the standard of care globally.
Innovative Technology Driving Change
Alesi Surgical's proprietary Ultravision platform technology offers a groundbreaking alternative to traditional smoke management products. Unlike conventional methods that rely on suction and mechanical filtration, Ultravision employs electrostatic precipitation to actively remove surgical smoke at the point of generation.
The first-generation Ultravision system has already been deployed in over 50,000 laparoscopic and robotic procedures across Europe, the United States, and Japan. Independent industry studies have demonstrated that in laparoscopic surgery, this technology removes smoke from the atmosphere up to 225 times faster than competing solutions.
Funding to Fuel Expansion and Development
The newly secured £7 million investment will support Alesi Surgical's international commercial expansion and further development of their next-generation Ultravision2 platform. This comes at a crucial time as regulatory frameworks around surgical smoke control continue to tighten worldwide.
Dr Dominic Griffiths, founder and chief executive of Alesi Surgical, emphasized the importance of their technology: "Electrosurgical tools have revolutionized modern surgery but simultaneously generate surgical smoke that compromises both surgical quality and efficiency while posing health risks to operating theatre staff. For years, available solutions forced difficult trade-offs between effectiveness and workflow disruption, which has slowed industry-wide adoption."
"As awareness grows that smoke management is integral to surgical safety and efficiency, solutions like our FDA-approved and CE-marked Ultravision2—which tackles smoke at its source—are becoming increasingly vital for supporting the next generation of minimally invasive and robotic procedures," Dr Griffiths added.
Investor Confidence in Market Transformation
Isobel Egemole, investment director at IW Capital, expressed strong confidence in Alesi Surgical's approach: "Surgical smoke is becoming an increasingly critical priority for hospitals worldwide, with growing needs to address both visibility and safety in operating rooms, supported by strengthening regulatory and compliance tailwinds. Solutions that integrate seamlessly into surgical workflows will define the next phase of adoption."
"Alesi Surgical offers a fundamentally different approach to smoke management that addresses the problem at its source. As the industry moves toward smoke-free operating theatres becoming the norm, Ultravision2 is exceptionally well positioned to play a pivotal role in this transformation," Egemole concluded.
This significant investment round represents a major vote of confidence in Cardiff's growing medtech sector and positions Alesi Surgical at the forefront of addressing one of healthcare's most persistent operational challenges.
